Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Pacira BioSciences, Inc. (NASDAQ: PCRX) is a pharmaceutical preparation manufacturing company focused on non-opioid pain therapies, and its news flow reflects this specialized focus. Company announcements frequently highlight developments related to its three commercial-stage products—EXPAREL, ZILRETTA and iovera°—as well as its gene therapy candidate PCRX-201 for osteoarthritis of the knee.
On this page, readers can follow Pacira news such as commercial partnerships, clinical data, manufacturing updates and shareholder-related events. Recent releases include an agreement granting LG Chem exclusive rights to commercialize EXPAREL in select Asia-Pacific markets, preliminary revenue updates emphasizing EXPAREL sales, and data from a pilot study showing favorable safety and pain reduction with iovera° compared with radiofrequency ablation in chronic low back pain.
Pacira also issues news about its participation in scientific and investor conferences, including presentations at major healthcare conferences, and its involvement in collaborative research efforts. For example, the company announced that it joined the PROBE Consortium, a public‑private initiative using big data and AI to improve osteoarthritis research and care, and that it will contribute data from its ASCEND study of PCRX-201.
In addition, Pacira’s news includes corporate and financial updates such as preliminary unaudited revenue results, share repurchase activity, inducement equity grants under its inducement plan, and operational changes like workforce reductions linked to manufacturing efficiency improvements. External parties such as DOMA Perpetual Capital Management LLC have also issued public letters and proxy-related communications concerning Pacira’s governance and strategic options.
Investors, analysts and healthcare professionals can use this news feed to monitor product performance, pipeline progress, strategic partnerships, financing developments and shareholder actions that may influence the outlook for PCRX stock and Pacira’s role in non-opioid pain management.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 9:00 AM ET in New York. The live audio of the event can be accessed via the company's website, and a replay will be available for two weeks thereafter.
Pacira is dedicated to providing non-opioid treatment options, including three commercial-stage products: EXPAREL, ZILRETTA, and ioveraº. The company aims to redefine opioid usage and address chronic pain and other debilitating conditions.
Pacira BioSciences partnered with the National Senior Games Association to achieve a GUINNESS WORLD RECORDS title for the Largest Game of Freeze Dance, held on May 16, 2022, with 1,308 participants in Fort Lauderdale, Florida. This event highlighted the company's non-opioid pain relief device, iovera°, which provides up to 90 days of osteoarthritis pain relief. Amber Sears from Pacira emphasized the initiative's role in promoting non-opioid options for chronic pain management, aiming to educate patients about viable alternatives to opioid treatments.
Pacira BioSciences reported preliminary net product sales for April 2022, with EXPAREL achieving $44.8 million, marking a 109% increase in average daily sales compared to April 2021. Sales of iovera° were $1.1 million, down from $1.5 million in the previous year. The company remains financially strong with an adjusted EBITDA of $53.8 million for Q1 2022. Despite ongoing pandemic-related challenges impacting elective surgeries, Pacira's leadership anticipates robust revenue growth. The company has not provided 2022 financial guidance due to uncertainties surrounding COVID-19.
TAMPA, Fla., May 10, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences (NASDAQ: PCRX) will participate in two upcoming healthcare conferences:
- RBC Capital Markets Global Healthcare Conference on May 17 at 8:00 AM ET.
- H.C. Wainwright Global Virtual Investment Conference on May 24 at 7:00 AM ET.
Live audio can be accessed on the company’s website, with replays available for two weeks post-events. Pacira's commitment lies in providing non-opioid pain management solutions.
Pacira BioSciences (Nasdaq: PCRX) reported a strong first quarter of 2022, with total revenues reaching $158 million, marking a 33% increase year-over-year. Net income was $6.8 million or $0.15 per share, while adjusted EBITDA stood at $53.8 million. Significant sales growth for EXPAREL at $129.2 million reflects operational resilience amid COVID-related challenges. The successful integration of the Flexion acquisition contributed to ZILRETTA's sales of $23.6 million. Looking forward, Pacira is optimistic about upcoming clinical studies and new product registrations.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will announce its first quarter financial results on May 4, 2022, before U.S. markets open. A conference call will follow at 8:30 a.m. ET, with participation options available for both domestic and international callers. The call will also be accessible via webcast on the company’s investor page. Pacira aims to provide non-opioid pain management solutions and has three commercial treatments: EXPAREL, ZILRETTA, and iovera, focusing on reducing opioid reliance.
Pacira BioSciences (Nasdaq: PCRX) announced record net product sales of EXPAREL totaling $51.2 million for March 2022, reflecting a 116% increase over March 2021. For Q1 2022, preliminary revenues range from $157.4 million to $158.4 million, up from $119.0 million in Q1 2021. Sales of ZILRETTA are estimated between $23.0 million and $24.0 million, down slightly from $24.6 million in Q1 2021. The company is not providing full-year 2022 revenue guidance due to ongoing uncertainties related to COVID-19's impact on elective surgeries.
Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 8:45 AM ET. Interested parties can access the live audio on the company’s events page. A replay will be available for two weeks post-event.
Pacira focuses on providing non-opioid treatment options for patients, with commercial-stage products like EXPAREL®, ZILRETTA®, and ioveraº®. The company aims to redefine opioid use and addresses conditions involving the sympathetic nervous system.
Pacira BioSciences (Nasdaq: PCRX) reported preliminary unaudited net product sales for EXPAREL and iovera° for February 2022. EXPAREL sales reached $41.7 million, an increase of 17.2% from $35.6 million in February 2021, indicating average daily sales at 117% of the previous year. iovera° sales rose to $0.9 million, up from $0.7 million. The company noted ongoing challenges due to the COVID-19 pandemic impacting elective surgeries but did not provide financial guidance for 2022 due to uncertainties.
TAMPA, Fla., March 09, 2022 — Pacira BioSciences, Inc. (NASDAQ: PCRX) will participate in an analyst-led fireside chat at the Barclays Global Healthcare Conference on March 16, 2022, at 10:15 AM ET in Miami. Investors can listen to the live audio via the company's Events page, with a replay available for two weeks post-event. Pacira focuses on non-opioid treatments, offering products like EXPAREL for postsurgical pain management and ZILRETTA for osteoarthritis knee pain, aiming to reduce opioid reliance.